Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japan Open-Label Linerixibat Safety and Tolerability Extension Study for Cholestatic Pruritus in PBC
NCT07860710Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
A Phase 3 trial of linerixibat in pruritus, sponsored by GSK. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
linerixibat
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT07860710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07860710.